Leah Nyawira Githinji1, Diane M Gray1, Sipho Hlengwa1, Landon Myer2, Heather J Zar1. 1. 1 Department of Pediatrics and Child Health, Red Cross Children's Hospital and Medical Research Council Unit, Child and Adolescent Health, and. 2. 2 Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Abstract
RATIONALE: Lung disease is a common cause of mortality and morbidity in HIV-infected adolescents, but there is limited information on the spectrum of lung function impairment in adolescents on antiretroviral therapy. OBJECTIVES: To investigate lung function in HIV-infected adolescents on antiretroviral therapy in the Cape Town Adolescent Antiretroviral Cohort (Cape Town, South Africa). METHODS: A total of 515 South African adolescents, aged 9-14 years, stable on antiretroviral therapy for at least 6 months, underwent baseline lung function testing. Measures included spirometry, nitrogen multiple-breath washout, forced oscillation technique, 6-minute walk test, single-breath carbon monoxide diffusion testing, and bronchodilator response testing. A comparator group of 110 age- and ethnicity-matched HIV-uninfected adolescents was also tested. RESULTS: For the HIV-infected adolescents (mean [SD] age 12 [1.6] years, 52% male), the median (interquartile range) duration of antiretroviral therapy was 7.6 (4.6-9.2) years. The median (interquartile range) nadir CD4 was 510.5 (274-903) cells/mm3. HIV-infected adolescents had significantly lower FEV1, FVC, FEV1/FVC, diffusing capacity of carbon monoxide, respiratory system compliance, and functional residual capacity than HIV-uninfected adolescents (P < 0.05 for all associations). HIV-infected adolescents had higher airway resistance and lung clearance index than HIV-uninfected adolescents (P < 0.05 for all associations). Although generally small in magnitude, these differences remained significant after adjusting for age, sex, and height. In addition, age, sex, height, and history of past lower respiratory tract infection or pulmonary tuberculosis were associated with reduced lung function. CONCLUSIONS: Perinatally infected South African HIV-infected adolescents on antiretroviral therapy have lower lung function than uninfected adolescents. Prior lower respiratory tract infection or pulmonary tuberculosis is associated with lower lung function.
RATIONALE: Lung disease is a common cause of mortality and morbidity in HIV-infected adolescents, but there is limited information on the spectrum of lung function impairment in adolescents on antiretroviral therapy. OBJECTIVES: To investigate lung function in HIV-infected adolescents on antiretroviral therapy in the Cape Town Adolescent Antiretroviral Cohort (Cape Town, South Africa). METHODS: A total of 515 South African adolescents, aged 9-14 years, stable on antiretroviral therapy for at least 6 months, underwent baseline lung function testing. Measures included spirometry, nitrogen multiple-breath washout, forced oscillation technique, 6-minute walk test, single-breath carbon monoxide diffusion testing, and bronchodilator response testing. A comparator group of 110 age- and ethnicity-matched HIV-uninfected adolescents was also tested. RESULTS: For the HIV-infected adolescents (mean [SD] age 12 [1.6] years, 52% male), the median (interquartile range) duration of antiretroviral therapy was 7.6 (4.6-9.2) years. The median (interquartile range) nadir CD4 was 510.5 (274-903) cells/mm3. HIV-infected adolescents had significantly lower FEV1, FVC, FEV1/FVC, diffusing capacity of carbon monoxide, respiratory system compliance, and functional residual capacity than HIV-uninfected adolescents (P < 0.05 for all associations). HIV-infected adolescents had higher airway resistance and lung clearance index than HIV-uninfected adolescents (P < 0.05 for all associations). Although generally small in magnitude, these differences remained significant after adjusting for age, sex, and height. In addition, age, sex, height, and history of past lower respiratory tract infection or pulmonary tuberculosis were associated with reduced lung function. CONCLUSIONS: Perinatally infected South African HIV-infected adolescents on antiretroviral therapy have lower lung function than uninfected adolescents. Prior lower respiratory tract infection or pulmonary tuberculosis is associated with lower lung function.
Authors: Young-Jee Kim; Graham L Hall; Kathy Christoph; Rebeka Tabbey; Zhangsheng Yu; Robert S Tepper; Howard Eigen Journal: Pediatr Pulmonol Date: 2011-11-11
Authors: Paul D Robinson; Philipp Latzin; Sylvia Verbanck; Graham L Hall; Alexander Horsley; Monika Gappa; Cindy Thamrin; Hubertus G M Arets; Paul Aurora; Susanne I Fuchs; Gregory G King; Sooky Lum; Kenneth Macleod; Manuel Paiva; Jane J Pillow; Sarath Ranganathan; Sarah Ranganathan; Felix Ratjen; Florian Singer; Samatha Sonnappa; Janet Stocks; Padmaja Subbarao; Bruce R Thompson; Per M Gustafsson Journal: Eur Respir J Date: 2013-02-08 Impact factor: 16.671
Authors: Matthew R Gingo; Sally E Wenzel; Chad Steele; Cathy J Kessinger; Lorrie Lucht; Tammi Lawther; Michelle Busch; Maria E Hillenbrand; Renee Weinman; William A Slivka; Deborah K McMahon; Yingze Zhang; Frank C Sciurba; Alison Morris Journal: J Allergy Clin Immunol Date: 2011-12-15 Impact factor: 10.793
Authors: Rashida A Ferrand; Sujal R Desai; Charlotte Hopkins; Caroline M Elston; Susan J Copley; Kusum Nathoo; Chiratidzo E Ndhlovu; Shungu Munyati; Richard D Barker; Robert F Miller; Tsitsi Bandason; Athol U Wells; Elizabeth L Corbett Journal: Clin Infect Dis Date: 2012-04-02 Impact factor: 20.999
Authors: Silvia Ulrich; Florian F Hildenbrand; Ursula Treder; Manuel Fischler; Stephan Keusch; Rudolf Speich; Margrit Fasnacht Journal: BMC Pulm Med Date: 2013-08-05 Impact factor: 3.317
Authors: Engi F Attia; Elizabeth Maleche-Obimbo; T Eoin West; Lilian Ndukwe-Wambutsi; Catherine Kiptinness; Anthony Cagle; Christine J McGrath; Celestine K Mugambi; Neveen G El Antouny; Sherry Eskander; Michael H Chung; Kristina Crothers Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Lisa J Frigati; Jennifer Jao; Sana Mahtab; Nana-Akua Asafu Agyei; Mark F Cotton; Landon Myer; Heather J Zar Journal: AIDS Res Hum Retroviruses Date: 2018-09-25 Impact factor: 2.205
Authors: Engi F Attia; Hellen Moraa; Elizabeth Maleche-Obimbo; Dalton Wamalwa; Laurén A Gómez; Sarah Rylance; Rumbidzayi Vundla; Rashida A Ferrand; Catherine J Karr; Grace C John-Stewart; Sarah F Benki-Nugent Journal: J Acquir Immune Defic Syndr Date: 2022-01-01 Impact factor: 3.771
Authors: Carmen Gonzalez-Martinez; Katharina Kranzer; Grace McHugh; Elizabeth L Corbett; Hilda Mujuru; Mark P Nicol; Sarah Rowland-Jones; Andrea M Rehman; Tore J Gutteberg; Trond Flaegstad; Jon O Odland; Rashida A Ferrand Journal: Trials Date: 2017-12-28 Impact factor: 2.279
Authors: Dan Hameiri-Bowen; Evgeniya Sovershaeva; Trond Flaegstad; Tore Jarl Gutteberg; Lucky Gift Ngwira; Victoria Simms; Andrea M Rehman; Grace Mchugh; Tsitsi Bandason; Rashida Abbas Ferrand; Sarah Rowland-Jones; Louis-Marie Yindom Journal: AIDS Date: 2021-09-01 Impact factor: 4.632